TY - JOUR
T1 - Management of patients with advanced prostate cancer in the Asia Pacific region
T2 - ‘real-world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017
AU - ANZUP Cancer Trials Group
AU - Chiong, Edmund
AU - Murphy, Declan G.
AU - Akaza, Hideyuki
AU - Buchan, Nicholas C.
AU - Chung, Byung Ha
AU - Kanesvaran, Ravindran
AU - Khochikar, Makarand
AU - Letran, Jason
AU - Lojanapiwat, Bannakij
AU - Ng, Chi fai
AU - Ong, Teng
AU - Pu, Yeong Shiau
AU - Saad, Marniza
AU - Schubach, Kathryn
AU - Türkeri, Levent
AU - Umbas, Rainy
AU - Le Chuyen, Vu
AU - Williams, Scott
AU - Ye, Ding Wei
AU - Davis, Ian D.
N1 - Publisher Copyright:
© 2018 The Authors BJU International © 2018 BJU International Published by John Wiley & Sons Ltd
PY - 2019/1
Y1 - 2019/1
N2 - Objective: The Asia Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2018) brought together 20 experts from 15 APAC countries to discuss the real-world application of consensus statements from the second APCCC held in St Gallen in 2017 (APCCC 2017). Findings: Differences in genetics, environment, lifestyle, diet and culture are all likely to influence the management of advanced prostate cancer in the APAC region when compared with the rest of the world. When considering the strong APCCC 2017 recommendation for the use of upfront docetaxel in metastatic castration-naïve prostate cancer, the panel noted possible increased toxicity in Asian men receiving docetaxel, which would affect this recommendation in the APAC region. Although androgen receptor-targeting agents appear to be well tolerated in Asian men with metastatic castration-resistant prostate cancer, access to these drugs is very limited for financial reasons across the region. The meeting highlighted that cost and access to contemporary treatments and technologies are key factors influencing therapeutic decision-making in the APAC region. Whilst lower cost/older treatments and technologies may be an option, issues of culture and patient or physician preference mean, these may not always be acceptable. Although generic products can reduce cost in some countries, costs may still be prohibitive for lower-income patients or communities. The panellists noted the opportunity for a coordinated approach across the APAC region to address issues of access and cost. Developments in technologies and treatments are presenting new opportunities for the diagnosis and treatment of advanced prostate cancer. Differences in genetics and epidemiology affect the side-effect profiles of some drugs and influence prescribing. Conclusions: As the field continues to evolve, collaboration across the APAC region will be important to facilitate relevant research and collection and appraisal of data relevant to APAC populations. In the meantime, the APAC APCCC 2018 meeting highlighted the critical importance of a multidisciplinary team-based approach to treatment planning and care, delivery of best-practice care by clinicians with appropriate expertise, and the importance of patient information and support for informed patient choice.
AB - Objective: The Asia Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2018) brought together 20 experts from 15 APAC countries to discuss the real-world application of consensus statements from the second APCCC held in St Gallen in 2017 (APCCC 2017). Findings: Differences in genetics, environment, lifestyle, diet and culture are all likely to influence the management of advanced prostate cancer in the APAC region when compared with the rest of the world. When considering the strong APCCC 2017 recommendation for the use of upfront docetaxel in metastatic castration-naïve prostate cancer, the panel noted possible increased toxicity in Asian men receiving docetaxel, which would affect this recommendation in the APAC region. Although androgen receptor-targeting agents appear to be well tolerated in Asian men with metastatic castration-resistant prostate cancer, access to these drugs is very limited for financial reasons across the region. The meeting highlighted that cost and access to contemporary treatments and technologies are key factors influencing therapeutic decision-making in the APAC region. Whilst lower cost/older treatments and technologies may be an option, issues of culture and patient or physician preference mean, these may not always be acceptable. Although generic products can reduce cost in some countries, costs may still be prohibitive for lower-income patients or communities. The panellists noted the opportunity for a coordinated approach across the APAC region to address issues of access and cost. Developments in technologies and treatments are presenting new opportunities for the diagnosis and treatment of advanced prostate cancer. Differences in genetics and epidemiology affect the side-effect profiles of some drugs and influence prescribing. Conclusions: As the field continues to evolve, collaboration across the APAC region will be important to facilitate relevant research and collection and appraisal of data relevant to APAC populations. In the meantime, the APAC APCCC 2018 meeting highlighted the critical importance of a multidisciplinary team-based approach to treatment planning and care, delivery of best-practice care by clinicians with appropriate expertise, and the importance of patient information and support for informed patient choice.
KW - advanced prostate cancer
KW - castration-naïve prostate cancer
KW - castration-resistant prostate cancer
KW - cost and access to treatment
KW - high-risk localised prostate cancer
KW - oligometastatic prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85052790498&partnerID=8YFLogxK
U2 - 10.1111/bju.14489
DO - 10.1111/bju.14489
M3 - Review article
C2 - 30019467
AN - SCOPUS:85052790498
SN - 1464-4096
VL - 123
SP - 22
EP - 34
JO - BJU International
JF - BJU International
IS - 1
ER -